Previously the IN substitutions V75I, Q148R, V151I, and G163R were reported as being associated with BMS-707035 resistance [48] , although no indication was given as to the resistance severity associated with each substitution. BMS-707035 is an HIV-1 integrase (IN) inhibitor. BMS-707035 was scheduled to be evaluated in a Phase II study to assess the antiretroviral activity, safety, pharmacodynamics, and pharmacokinetics in 50 HIV-infected subjects using a 10-day randomized, double-blind, placebo-controlled, ascending multiple-dose study design |
